Amgen Inc. (AMGN) News
Track canonical SquawkNews coverage tagged to AMGN, Amgen Inc.. This hub brings together deduplicated headlines about united states, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 69 indexed stories across 33 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
Sling Therapeutics raises $123 million for thyroid eye disease late-stage trial
Sling Therapeutics said it raised $123 million to advance a late-stage trial of its experimental oral drug for thyroid eye disease.
EQUITY | Sep 16, 2026, 11:00 AM UTC
M
Bristol Myers, Ono sue Amgen to block Opdivo biosimilar
Bristol Myers Squibb and Ono Pharmaceutical sued Amgen in Delaware federal court seeking to block Amgen’s proposed U.S. biosimilar of Opdivo.
EQUITY | Sep 15, 2026, 08:25 PM UTC
L
Bristol Myers sues Amgen over proposed Opdivo biosimilar
By Blake BrittainBristol Myers Squibb NYSE:BMY and Ono Pharmaceutical TSE:4528 have sued Amgen NASDAQ:AMGN in Delaware federal court, seeking to block Amgen's proposed U.S. biosimilar of their blockbuster cancer immunoth
NEWS | Sep 15, 2026, 05:29 PM UTC
L
AMGN: Quarterly growth and pipeline advances set the stage for durable, innovation-driven expansion
Strong quarterly growth was driven by key products and robust pipeline progress, including landmark phase III results for IMDELLTRA and positive data for TEZSPIRE. Strategic focus remains on innovation, disciplined capit
NEWS | Sep 15, 2026, 04:31 PM UTC
L
HBA India Summit Calls For Leaders To Command The AI Shift
Hyderabad summit highlights AI, GCCs, commercial acumen and influence as India takes on a larger role in global healthcare leadershipThe Healthcare Businesswomen’s Association (HBA) India hosted the third edition of its
NEWS | Sep 15, 2026, 08:32 AM UTC
H
Notable healthcare headlines for the week: UnitedHealth, Amgen, and CooperCompanies in focus
Wall Street rallied on Friday after the latest consumer inflation report came in broadly in line with expectations, helping ease concerns over price pressures and supporting a rebound across risk assets.On Friday, the Do
NEWS | Sep 13, 2026, 01:11 PM UTC
H
Bulls and Bears: GameStop, Marvell, Robinhood
examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories. U.S. stocks ended the week lower despite a Friday rebound, as surging oil prices, rising Treasury
LIVE | Sep 12, 2026, 12:50 PM UTC
L
Heart Disease, a Historic Strength for Big Pharma, Becomes a Weakness - Heard on the Street — WSJ
By David WainerThere is a strange paradox haunting healthcare investing right now.Heart disease remains humanity's top killer, yet for drugmakers and Wall Street, it is becoming one of the hardest places to make money.Th
NEWS | Sep 12, 2026, 09:30 AM UTC
H
Chip stocks lead Nasdaq's weekly gains; Amgen plunges after trial setback
The Nasdaq Composite Index NYSE:COMP climbed on Friday alongside major Wall Street indexes after the latest consumer inflation report came in largely in line with expectations. It closed +0.96% higher after jumping by ov
NEWS | Sep 11, 2026, 08:31 PM UTC
L
Amgen price target cut to $425 by HSBC
HSBC cut its Amgen rating to Hold from Buy and lowered its price target to $425.00 from $445.00, according to Benzinga via TradingView News.
EQUITY | Sep 10, 2026, 02:23 PM UTC
L
AMGEN to present at the Morgan Stanley 24th annual global healthcare conference
EQUITY | Sep 09, 2026, 08:01 PM UTC
L
25 dividend stocks to watch as market sentiment turns negative
Dividend-paying stocks gained renewed momentum Wednesday as investors shifted toward safety amid a slide in broader market averages.The blue-chip Dow Jones Industrial Average TVC:DJI dropped to a new one-month low while
ENERGY | Sep 09, 2026, 04:51 PM UTC
L
Barclays analyst says outcome is worst for Amgen
A Barclays analyst, Emily Field, said the Novartis heart-disease drug announcement was “the worst possible outcome for Amgen,” adding it cast doubt on one of Amgen’s major drugs.
EQUITY | Sep 08, 2026, 09:30 PM UTC
M
Amgen-AstraZeneca Imdelltra plus Imfinzi improves survival in SCLC trial
Amgen said its Imdelltra targeted immunotherapy with AstraZeneca’s Imfinzi significantly improved overall survival in extensive-stage small-cell lung cancer in a late-stage trial, the companies said on Tuesday.
EQUITY | Sep 08, 2026, 08:26 PM UTC
H
Amgen slides after Novartis pelacarsen failure report
Amgen shares were down more than 9% and were on pace for its largest daily decrease since October 2000. The move followed Novartis’ announcement that pelacarsen failed to reduce cardiovascular event risk.
EQUITY | Sep 08, 2026, 06:20 PM UTC
H
What's Moving Markets Today? — WSJ
By Shradha DineshMajor stock indexes faced pressure on Tuesday with a fresh slate of geopolitical tensions weighing on investors. The Dow industrials are down about 1%. Meanwhile, quantum computing stocks are on the rise
GEOPOLITICS | Sep 08, 2026, 05:49 PM UTC
H
Stocks slip as Brent above $97 reignites rate-hike fears
U.S. stocks fell Tuesday as crude oil extended higher, pushing the 10-year Treasury yield above 4.8% and reviving bets the Federal Reserve could raise rates next week. The Dow led declines, while Amgen was the biggest dr
EARNINGS | Sep 08, 2026, 05:13 PM UTC
H
Amgen helps drag Dow lower as oil jumps on Saudi strikes
U.S. stocks fell to start the week, with the Dow down about 550 points (~1%). S&P 500 and Nasdaq were down less than 0.5%, as Amgen shares dropped and oil rose on Saudi strikes.
COMMODITIES | Sep 08, 2026, 04:29 PM UTC
M
AstraZeneca says Imfinzi and Imdelltra improved survival
AstraZeneca said Imfinzi combined with Amgen’s Imdelltra significantly improved overall survival for extensive-stage small-cell lung cancer patients in a late-stage trial.
EQUITY | Sep 08, 2026, 01:51 PM UTC
M
AstraZeneca/Amgen Imfinzi–Imdelltra combo improves survival goal
AstraZeneca said Imfinzi combined with Amgen’s Imdelltra significantly improved overall survival in first-line extensive-stage small cell lung cancer in a late-stage trial, meeting its main survival goal.
EQUITY | Sep 08, 2026, 01:14 PM UTC
L
AMGN Imdelltra plus Imfinzi shows improved overall survival
TradeXchange Newsdesk says AMGN’s Imdelltra in combination with Imfinzi demonstrated landmark improvement in overall survival in first-line extensive-stage small cell lung cancer.
EQUITY | Sep 08, 2026, 01:02 PM UTC
L
BMO downgrades Amgen to Market Perform from Outperform
BMO Capital downgraded Amgen to Market Perform from Outperform, according to Benzinga ratings actions.
EQUITY | Sep 08, 2026, 12:25 PM UTC
L
Cantor Fitzgerald maintains AMGN $400 price target
Cantor Fitzgerald maintained its $400.00/share price target for AMGN, according to Benzinga ratings actions.
EQUITY | Sep 08, 2026, 11:09 AM UTC
H
Intel, Amgen, Novartis, Bloom Energy, and More Stocks That Explain Today's Market — Barrons.com
By George GloverStock futures were dropping on Tuesday as oil prices neared $100 a barrel, bolstering the case for the Federal Reserve to hike interest rates next week.Artificial-intelligence stocks were rising despite t
MACRO | Sep 08, 2026, 11:06 AM UTC
M
Amgen inherits a higher proof bar after rival trial outcome
Amgen is facing a tougher burden of proof as its shares stood at $437.23, following Novartis’s Phase 3 pelacarsen trial results that lowered Lp(a) but failed to cut major cardiovascular events.
EQUITY | Sep 07, 2026, 09:46 PM UTC
M
Novartis shares slide after-hours after heart-trial fails to cut events
Novartis shares sank after-hours after a heart-disease trial failed to show that lowering an inherited risk factor prevented heart attacks and strokes. NVS closed at $159.99, then slipped as much as about 7% after hours.
EQUITY | Sep 04, 2026, 10:52 PM UTC
L
Wells Fargo keeps Amgen at equal weight; raises price target to $435
Wells Fargo maintained an equal-weight rating on Amgen and raised its price target to $435.00 per share from $400.00, according to Benzinga.
EQUITY | Sep 04, 2026, 06:48 PM UTC
L
AMGN - AMGEN TO PRESENT AT THE 2026 WELLS FARGO HEALTHCARE CONFERENCE
AMGN - AMGEN TO PRESENT AT THE 2026 WELLS FARGO HEALTHCARE CONFERENCE
EQUITY | Sep 02, 2026, 08:02 PM UTC
L
Amgen to present at 2026 Wells Fargo Healthcare Conference
Amgen will present at the 2026 Wells Fargo Healthcare Conference at 11:00 a.m. ET on Thursday, September 10, 2026. CFO Thomas Dittrich and Paul Burton, M.D., Ph.D. are listed to participate.
EQUITY | Sep 02, 2026, 08:01 PM UTC
M
Amgen hit as UK suspends Tavneos for new patients
Amgen faces a widening regulatory threat to rare-disease drug Tavneos. The U.K. suspended use for new patients and set a path toward full withdrawal in March 2027, after similar Europe action and proposed U.S. withdrawal
EQUITY | Sep 02, 2026, 03:16 PM UTC
H
Investors Shrug Off Good News for Heart Patients From New Meds — Barrons.com
By Bill AlpertThis year's run in drug stocks gained vigor from new treatments for heart attacks and strokes. Maybe some of those stocks are losing wind.At this past weekend's congress of the European Society of Cardiolog
GEOPOLITICS | Sep 01, 2026, 07:27 PM UTC
M
UK regulator suspends Tavneos use for new patients
Britain’s medicines regulator suspended the use and sale of Amgen’s Tavneos to new patients, citing that the main study supporting approval was unreliable.
REGULATION | Sep 01, 2026, 03:32 PM UTC
M
UK regulator suspends Amgen’s Tavneos for new patients
Britain’s medicines regulator suspended the use and sale of Amgen’s rare-disease drug Tavneos to new patients, saying the main study supporting its approval was unreliable.
REGULATION | Sep 01, 2026, 11:15 AM UTC
L
Trump administration to announce drug pricing deals
TradingView News reports the Trump administration will announce drug pricing deals.
EQUITY | Aug 31, 2026, 04:07 PM UTC
M
AMGN reports Repatha reduces risk of death in high-risk patients
Amgen said its Repatha reduced risk of death in patients at high risk for a first heart attack or stroke.
EQUITY | Aug 31, 2026, 07:19 AM UTC
L
Amgen says Tezspire safety profile matches approved indications
Amgen said Tezspire’s safety profile is consistent with its approved indications.
EQUITY | Aug 27, 2026, 06:32 AM UTC
M
AMGN TEZSPIRE® reports positive Phase 3 results in eosinophilic esophagitis
AMGN says its TEZSPIRE® showed positive Phase 3 results across the co-primary and all key secondary endpoints in eosinophilic esophagitis.
EQUITY | Aug 27, 2026, 06:00 AM UTC
H
White House to announce new drug pricing deals with biotechs, Bloomberg News reports
White House to announce new drug pricing deals with biotechs, Bloomberg News reports
GEOPOLITICS | Aug 26, 2026, 05:06 PM UTC
M
Dow Jones closes 0.17% higher as Merck, Salesforce lead
The Dow Jones Index rose 89 points, or 0.17%, on Wednesday to close at 53,433, with Merck, Salesforce and Amgen leading gains and Caterpillar, Goldman Sachs and Honeywell International lagging.
EQUITY | Aug 19, 2026, 08:35 PM UTC
M
Dow Jones closes 0.20% lower as Salesforce, Cisco lead declines
The Dow Jones Index fell 108 points, or 0.20%, on Friday to close at 53732, with Salesforce, Cisco Systems and Amgen among the biggest drags.
EQUITY | Aug 14, 2026, 08:35 PM UTC
M
U.S.-China biotech rivalry drives pharma dealmaking, policy scrutiny
China has pulled ahead of the United States in two of six domains in a June Cure Innovation Index survey, while U.S. agencies and lawmakers move to screen biotech ties and licensing deals continue.
GEOPOLITICS | Aug 13, 2026, 02:41 AM UTC
H
Chubb, Toast And A Health Care Stock On CNBC’s ‘Final Trades’
On CNBC’s “ Halftime Report Final Trades,” Malcolm Ethridge, managing partner at Capital Area Planning Group, recommended Chubb Limited (NYSE: CB ) as his final trade. On the earnings front, Chubb, on July 21, reported s
EARNINGS | Aug 07, 2026, 12:05 PM UTC
H
Gold Jumps 4%, Dow Jones Smashes Record Highs: Stock Market Today
Gold ripped 4% higher to $4,233.89 an ounce on Wednesday, its biggest one-day advance since February, as a soft private payrolls report and easing energy costs knocked down the odds of another Federal Reserve rate hike.
EARNINGS | Aug 05, 2026, 06:14 PM UTC
H
Amgen shares are trading higher after the company reported better-than-expected Q2 financial results, raised its FY26 adjusted EPS guidance
Amgen shares are trading higher after the company reported better-than-expected Q2 financial results, raised its FY26 adjusted EPS guidance with its midpoint above estimates and raised its FY26 sales guidance above estim
EARNINGS | Aug 05, 2026, 02:06 PM UTC
M
Amgen Target Raised To $230 By Baird
Baird raises Amgen target price
EQUITY | Aug 05, 2026, 04:10 AM UTC
H
Amgen Raises FY Adjusted EPS Guidance
Amgen increases FY adjusted EPS guidance
EARNINGS | Aug 04, 2026, 08:07 PM UTC
H
Amgen Posts Q2 Revenue Of $10.05Bln
Amgen beats Q2 revenue estimate
EARNINGS | Aug 04, 2026, 08:07 PM UTC
H
Amgen Narrows FY2026 GAAP EPS Guidance from $15.62-$17.10 to $15.80-$17.08 vs $15.44 Est
Amgen (NASDAQ: AMGN ) narrows FY2026 GAAP EPS guidance from $15.62-$17.10 to $15.80-$17.08 vs $15.44 analyst estimate..
EARNINGS | Aug 04, 2026, 08:02 PM UTC
H
Amgen Raises FY2026 Adj EPS Guidance from $21.70-$23.10 to $22.30-$23.50 vs $22.35 Est; Raises FY2026 Sales Guidance from $37.100B-$38.500B
Amgen (NASDAQ: AMGN ) raises FY2026 Adj EPS guidance from $21.70-$23.10 to $22.30-$23.50 vs $22.35 analyst estimate. Raises FY2026 sales outlook from $37.100 billion-$38.500 billion to $38.200 billion-$39.400 billion vs
EARNINGS | Aug 04, 2026, 08:02 PM UTC
H
Amgen 2Q Adj EPS $6.29
Amgen beats 2Q EPS estimates
EARNINGS | Aug 04, 2026, 08:02 PM UTC
H
AMGN AMGN - AMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS
AMGN AMGN - AMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS
EARNINGS | Aug 04, 2026, 08:01 PM UTC
H
US Stocks: Earnings After Market
Multiple US companies report earnings
EARNINGS | Aug 04, 2026, 09:07 AM UTC
H
US Stocks: Earnings After Market
Multiple US companies report earnings
EARNINGS | Aug 03, 2026, 08:49 PM UTC
H
SpaceX Could Swing $204 Billion After Earnings
Earnings are set to hit the tape in a tight window on Tuesday, and the options market is already sketching out how much volatility traders expect once results and guidance land, according to Pro. This is a -selected watc
EARNINGS | Aug 03, 2026, 07:30 PM UTC
H
Amgen Identifies Unauthorized Activity
Amgen detects unauthorized data access
EQUITY | Jul 31, 2026, 08:08 PM UTC
L
AMGN Amgen - notes incident not expected to materially impact financial condition or results - SEC filing
AMGN Amgen - notes incident not expected to materially impact financial condition or results - SEC filing
RATES | Jul 31, 2026, 08:05 PM UTC
L
AMGN Amgen - identifies unauthorized activity in third-party Cloud environments in July 2026 - SEC filing - Reports no impact to products, o
AMGN Amgen - identifies unauthorized activity in third-party Cloud environments in July 2026 - SEC filing - Reports no impact to products, operations, or financial reporting from incident - SEC filing - Reports exfiltrat
REGULATION | Jul 31, 2026, 08:04 PM UTC
L
Amgen Announces Q3 Dividend
Amgen declares Q3 dividend
EQUITY | Jul 30, 2026, 08:01 PM UTC
H
AMGN Gets CHMP Nod For Repatha
AMGN's Repatha gets CHMP approval
EQUITY | Jul 29, 2026, 01:01 PM UTC
L
AMGN: Barclays Raises Price Target
Barclays raises AMGN price target
EQUITY | Jul 29, 2026, 11:35 AM UTC